Treatment Options for Transplant-Ineligible Multiple Myeloma
Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: For transplant-ineligible patients, we traditionally had been using things like bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone, or VRd light, with lenalidomide maintenance therapy and that’s a perfectly good combination to use. The most recent MAIA trial [NCT02252172] data that were presented at the European [Hematology Association] Congress really did solidify the role for daratumumab [Darzalex], lenalidomide, dexamethasone in patients who are transplant-ineligible because there’s both a PFS [progression-free survival] and an overall survival advantage. It sounds like there’s going to be some nice quality-of-life data to suggest that these people are doing better despite being on therapy for longer.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
